Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer Genetics has again lowered the amount it expects to bring in from its pending initial public offering, the Rutherford, NJ-based firm disclosed in a document filed with the US Securities and Exchange Commission late on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.